Oncoustics Secures $5.5M CAD to Advance AI Innovations in Ultrasound & Address Unmet Clinical Needs in Liver Disease

July 22, 2022
1 min read

Congratulations to Oncoustics on raising a $5.5 million CAD ($4.3 million USD) seed funding round to disrupt the liver disease diagnostic space. The startup has made early disease detection, diagnosis, and patient management easier, less-invasive, and more efficient for clinicians and patients alike.

The all-equity seed financing was co-led by Creative Ventures and Saltagen Ventures, with participation from NorthSpring Capital Partners, Fraser Kearney Capital, Pallasite Ventures, and radiologist Dr. Chen Fong. To date, Oncoustics has successfully raised over $5 million USD in funding.

Oncoustics has amassed the largest ultrasound signal dataset and the largest RF signal data set in the world. The startup applies machine learning to raw sound signals that are produced by common ultrasound machines, and turns them into meaningful clinical data—specifically, tissue acoustic evaluations that enable the startup to make tissue characterizations and to diagnose early liver disease.

We are immensely proud of Beth Rogozinski, Ahmed El Kaffas, and the entire team at Oncoustics on this amazing milestone. We are excited to continue supporting the startup as they execute and scale to one day completely eliminate the need for high-end imaging or painful and invasive biopsies for the entire patient population.

Tagged: featured


MaRS Discovery District 
101 College Street
Suite 250, Heritage Building


L'Espace CDPQ 
3 Place Ville Marie
Bureau 12350

© 2024 Two Small Fish Ventures